What is Teckro, Inc.?
Headquartered in Limerick, Ireland, Teckro, Inc. provides a sophisticated digital engagement platform designed to streamline the execution of clinical trials. In an industry historically burdened by fragmented communication and manual processes, Teckro offers a centralized solution that connects all study stakeholders. This digital transformation of the trial environment ensures that global pharmaceutical companies and biotech firms can maintain rigorous standards across all therapeutic areas and trial phases. By digitizing the protocol and facilitating real-time interaction, Teckro effectively reduces the friction inherent in clinical research, positioning itself as an essential utility for modern drug development.
How much funding has Teckro, Inc. raised?
Teckro, Inc. has raised a total of $41M across 3 funding rounds:
Series A
$6M
Series B
$10M
Series C
$25M
Series A (2016): $6M with participation from Founders Fund and Enterprise Ireland
Series B (2017): $10M led by Sands Capital Ventures, Section 32, and Founders Fund
Series C (2019): $25M supported by Section 32, Northpond Ventures, Founders Fund, Borealis Ventures, and Sands Capital Ventures
Key Investors in Teckro, Inc.
Founders Fund
A prominent venture capital firm that invests in transformative companies across all stages, known for its founder-friendly approach and history of backing iconic technology enterprises.
Section 32
A venture capital firm founded by Bill Maris that focuses on investing in cutting-edge technology and supporting visionary entrepreneurs at the forefront of innovation.
Sands Capital Ventures
An established investment management firm that manages equity mutual funds and provides strategic capital to high-growth companies in public and private markets.
What's next for Teckro, Inc.?
With the backing of major venture capital firms, Teckro is well-positioned to accelerate its market penetration and enhance its technological capabilities. The current lifecycle stage, characterized by major enterprise-level funding, suggests a strategic focus on scaling global operations and deepening the integration of its platform within the pharmaceutical ecosystem. Future growth will likely center on expanding the platform's analytical features and broadening its reach into new therapeutic markets. As the demand for decentralized and digital-first clinical trials continues to rise, Teckro's established infrastructure provides a robust foundation for sustained long-term value creation and industry leadership.
See full Teckro, Inc. company page
